Cilengitide
- Generic Name
- Cilengitide
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40N8O7
- CAS Number
- 188968-51-6
- Unique Ingredient Identifier
- 4EDF46E4GI
- Background
Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01782976
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Target Recruit Count
- 28
- Registration Number
- NCT01517776
- Locations
- 🇩🇪
University Children´s Hospital, Halle, Saxonia-Anhalt, Germany
Pharmacokinetics in Subjects With Renal Impairment
- Conditions
- Renal Impairment
- Interventions
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT01504165
- Locations
- 🇩🇪
CRS Clincial Research Services Kiel GmbH, Kiel, Germany
🇩🇪For Research Sites contact Merck KGaA Communication Center in, Darmstadt, Germany
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
- Conditions
- Estrogen Receptor NegativeHER2/Neu NegativeMale Breast CarcinomaStage IIIB Breast CancerStage IV Breast CancerAdult Solid NeoplasmProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple-Negative Breast CarcinomaStage IIIC Breast Cancer
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01276496
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Radiation: Concomitant radiotherapyBiological: PharmacokineticBiological: PharmacogeneticBiological: Exploratory investigation
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 32
- Registration Number
- NCT01165333
- Locations
- 🇫🇷
Hôpital des Enfants, Groupe Hospitalier, Bordeaux, France
🇫🇷Centre Hospitalier Universitaire de Nantes, Nantes, France
🇫🇷Centre Léon Bérard, Lyon, France
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
- Conditions
- Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2011-07-26
- Target Recruit Count
- 48
- Registration Number
- NCT01124240
- Locations
- 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Solid NeoplasmRecurrent Adult Brain Neoplasm
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01122888
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- Bart Neyns
- Target Recruit Count
- 12
- Registration Number
- NCT01044225
- Locations
- 🇧🇪
ZNA Middelheim, Antwerpen, Belgium
🇧🇪Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium
🇧🇪GHdC Charleroi, Charleroi, Belgium
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
- Conditions
- Adult GlioblastomaAdult GliosarcomaRecurrent Adult Brain NeoplasmAdult Giant Cell Glioblastoma
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00979862
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Charlestown, Massachusetts, United States
Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer
- Conditions
- Lung CancerBrain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Universitätsmedizin Mannheim
- Target Recruit Count
- 19
- Registration Number
- NCT00884598
- Locations
- 🇩🇪
University Medical Center, Department of Surgery, Mannheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.